CAR T-Cell Therapy | Clinical

UCART19 Shows Promising Safety/Efficacy in Adult Patients With B-Cell ALL

November 30, 2022

Findings from the phase 1 CALM study evaluating the allogeneic genome-edited anti-CD19 chimeric antigen receptor T-cell product UCART19 show it can be safely used for patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

CD19-/CD22-CAR T Cells Elicits Durable Remissions in Children With R/R B-Cell ALL

November 22, 2022

In pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia, complete remissions were achieved in 99.0% of patients and their overall 12-month event-free survival was 73.5% with CD19-/CD22-chimeric antigen receptor therapy.

Allogeneic CAR T-Cell Therapy May Provide Alternate Options in ALL

October 24, 2022

In an interview with Targeted Oncology, Nitin Jain, MD, further discussed the ongoing research of allogeneic chimeric antigen receptor T cells as treatment for patients with ALL. He also notes what future research must examine to further the field.

Administering CAR T-Cell Therapy in the Community Setting

October 17, 2022

Peter A. McSweeney, MD, discusses the challenges that come with administering chimeric antigen receptor T-cell therapy. He also explains how CAR T cells entering the second-line may change the ways community practices choose treatments for their patients.